ReviewMarine drugs2016
Marine Algae as a Potential Source for Anti-Obesity Agents.
Review in Marine drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 176 citations in OpenAlex.
- Bioactivities of Lipid Extracts and Complex Lipids from Seaweeds: Current Knowledge and Future Prospects.Marine drugs · 2021Pooled it
- Effects of Supplementation with Microalgae Extract fromNutrients · 2024Trial
- Effects of Daily Kelp (Marine drugs · 2021Trial
- Chalinasterol attenuates ethanol-induced hepatic lipid accumulation by activating β-oxidation.Biomedical reports · 2026Article
- Marine-Algal-Derived Postbiotics Modulating the Gut Microbiota-Adipose Tissue Axis in Obesity: A New Frontier.Nutrients · 2025Review
- Chemical and Mechanistic Prediction Analysis of Anti-obesity Properties of Guang Hawthorn (Malus doumeri) Leaves using Network Analysis.Combinatorial chemistry & high throughput screening · 2025Article
- Seaweed in the Diet as a Source of Bioactive Metabolites and a Potential Natural Immunity Booster: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Artificial Intelligence in Natural Product Drug Discovery: Current Applications and Future Perspectives.Journal of medicinal chemistry · 2025Review
- Article
- Bioactive carbohydrate polymers from marine sources as potent nutraceuticals in modulating obesity: a review.Food science and biotechnology · 2024Review
- The role of algae, fungi, and insect-derived proteins and bioactive peptides in preventive and clinical nutrition.Frontiers in nutrition · 2024Review
- Algae in Biomedicine.Advances in experimental medicine and biology · 2024Review
- Anti-obesity effects of olivetol in adult zebrafish model induced by short-term high-fat diet.Scientific reports · 2023Article
- Rehashing Our Insight of Seaweeds as a Potential Source of Foods, Nutraceuticals, and Pharmaceuticals.Foods (Basel, Switzerland) · 2023Review
- Valuable pigments from microalgae: phycobiliproteins, primary carotenoids, and fucoxanthin.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2023Review
- Marine Macroalgae Polyphenols as Potential Neuroprotective Antioxidants in Neurodegenerative Diseases.Marine drugs · 2023Review
- Roles of Marine Macroalgae or Seaweeds and Their Bioactive Compounds in Combating Overweight, Obesity and Diabetes: A Comprehensive Review.Marine drugs · 2023Review
- Intra-Species Variations of Bioactive Compounds of Two Dictyota Species from the Adriatic Sea: Antioxidant, Antimicrobial, Dermatological, Dietary, and Neuroprotective Potential.Antioxidants (Basel, Switzerland) · 2023Article
- A comprehensive review on algal nutraceuticals as prospective therapeutic agent for different diseases.3 Biotech · 2023Review
- Pharmacological Treatments and Natural Biocompounds in Weight Management.Pharmaceuticals (Basel, Switzerland) · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major epidemic that poses a worldwide threat to human health, as it is also associated with metabolic syndrome, type 2 diabetes and cardiovascular disease. Therapeutic intervention through weight loss drugs, accompanied by diet and exercise, is one of the options for the treatment and management of obesity. However, the only approved anti-obesity drug currently available in the market is orlistat, a synthetic inhibitor of pancreatic lipase. Other anti-obesity drugs are still being evaluated at different stages of clinical trials, while some have been withdrawn due to their severe adverse effects. Thus, there is a need to look for new anti-obesity agents, especially from biological sources. Marine algae, especially seaweeds are a promising source of anti-obesity agents. Four major bioactive compounds from seaweeds which have the potential as anti-obesity agents are fucoxanthin, alginates, fucoidans and phlorotannins. The anti-obesity effects of such compounds are due to several mechanisms, which include the inhibition of lipid absorption and metabolism (e.g., fucoxanthin and fucoidans), effect on satiety feeling (e.g., alginates), and inhibition of adipocyte differentiation (e.g., fucoxanthin). Further studies, especially testing bioactive compounds in long-term human trials are required before any new anti-obesity drugs based on algal products can be developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.